Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03814317 · ClinicalTrials.gov registry record · Phase 2
Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension
A Phase 2 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT03814317 is a Phase 2 study that has completed, run by University of Florida. The registered enrollment target is 5 participants.
The verdict
NCT03814317, a Phase 2 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study aims to evaluate the efficacy and safety of inhaled treprostinil in subjects with sarcoidosis-associated interstitial lung disease and pulmonary hypertension.
Interventions
- DRUG Inhaled Treprostinil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-01-30 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03814317
The ClinicalTrials.gov registry entry for NCT03814317 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Inhaled Treprostinil is the first listed.
NCT03814317 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03814317 about?
NCT03814317 is a clinical study titled "Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension". This study aims to evaluate the efficacy and safety of inhaled treprostinil in subjects with sarcoidosis-associated interstitial lung disease and pulmonary hypertension.
What is the current status of trial NCT03814317?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2020-01-30. Estimated completion is 2025-12-31.
What interventions are being tested in trial NCT03814317?
The interventions under investigation include: Inhaled Treprostinil (DRUG).
Who is sponsoring clinical trial NCT03814317?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.